India Nuclear Medicine and Radiopharmaceuticals Market by Type of Product, Type of Radioisotope, Imaging Modality, Application, and End User - Trends and Forecast Till 2035

INDIA NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MARKET: OVERVIEW

The Indian nuclear medicine and radiopharmaceuticals market is valued at USD 0.72 billion in the current year and is projected to reach USD 2.10 billion by 2035, representing a CAGR of 12.6% during the forecast period.

India Nuclear Medicine and Radiopharmaceuticals Market: Growth and Trends

Nuclear medicine uses trace amounts of radioactive material, known as radiopharmaceuticals or radiotracers, to diagnose and treat disease at the molecular level. Unlike conventional radiology, which primarily captures anatomical structure, nuclear medicine imaging modalities such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) reveal how organs and tissues actually function, enabling earlier detection of cancer, cardiac ischemia, neurodegenerative disorders, and thyroid disease. Therapeutic radiopharmaceuticals extend this molecular targeting further, delivering cytotoxic radiation directly to diseased cells while sparing surrounding healthy tissue, a precision-medicine approach increasingly referred to as theranostics.

India's nuclear medicine ecosystem has historically been anchored by the Department of Atomic Energy (DAE) and its Board of Radiation and Isotope Technology (BRIT), which supply the majority of Tc-99m generators and related isotopes to hospitals nationwide. Over the past few years, this state-led backbone has been complemented by a fast-growing private radiopharmacy and cyclotron network, an expanding installed base of PET-CT and SPECT-CT systems across corporate hospital chains, and a wave of new FDG and gallium-68 production units being commissioned in metro and tier-1 cities. Rising cancer incidence, an aging population, growing awareness of early cancer and cardiac screening, and increasing insurance penetration for advanced diagnostic imaging are collectively pushing nuclear medicine and radiopharmaceuticals from a tertiary-care niche toward a core component of India's diagnostic and oncology care pathway.

Government policies are further reinforcing the market growth momentum. India's Department of Atomic Energy has been directing capital toward dedicated reactor and isotope production capacity to strengthen domestic radioisotope self-sufficiency and reduce reliance on imported medical isotopes, including public-private partnership models aimed at scaling up production of medically important radionuclides. Combined with the localization of PET tracer manufacturing and the entry of global radiopharmaceutical majors into Indian distribution and manufacturing partnerships, these developments are reshaping supply-chain economics for an industry that has traditionally been constrained by the short half-life of key isotopes.

Growth Drivers: Strategic Enablers of Market Expansion

The India nuclear medicine and radiopharmaceuticals market is being propelled by a convergence of epidemiological, infrastructural, and policy-driven forces. Rising cancer incidence and a growing burden of cardiovascular and neurological disease are driving demand for precise, function-based diagnostic imaging, positioning PET-CT and SPECT-CT as increasingly standard tools in oncology staging, cardiac perfusion assessment, and dementia workup. As hospital networks expand into tier-2 and tier-3 cities, the accompanying build-out of diagnostic imaging and nuclear medicine departments is widening patient access beyond India's traditional metro-centric hubs.

Government-backed investment in domestic radioisotope production is a second major enabler. Continued funding for dedicated reactor and cyclotron infrastructure under the Department of Atomic Energy, alongside public-private partnership models for isotope manufacturing, is reducing India's historical dependence on imported Tc-99m, Mo-99, and PET isotopes, while improving supply reliability for hospitals operating time-sensitive nuclear medicine procedures. This is complemented by growing private-sector investment in radiopharmacies and cyclotron facilities, which is shortening isotope transport times and expanding same-day radiotracer availability.

Additionally, the growing global clinical success of Lutetium-177-based and related therapies for prostate cancer and neuroendocrine tumors is increasing interest among Indian oncology centers and radiopharmaceutical developers in establishing domestic theranostic pathways. This trend is expected to support the emergence of a high-value therapeutic radiopharmaceuticals segment, complementing India's traditionally diagnostics-led radiopharmaceutical market. Finally, expanding health insurance coverage, rising per-capita healthcare spending, growing medical tourism for advanced cardiac and cancer diagnostics, and strategic collaborations between global radiopharmaceutical manufacturers and Indian hospital chains and distributors are together reinforcing sustained, long-term demand for radiopharmaceutical products and nuclear medicine services across the country.

Market Challenges: Critical Barriers Impeding Progress

Despite strong underlying demand, several structural challenges continue to constrain the pace of growth in the India nuclear medicine and radiopharmaceuticals market. The short half-life of key radioisotopes, including Tc-99m and 18F-FDG, requires production facilities to be located close to end-use hospitals, and India's cyclotron and reactor-based isotope production capacity remains concentrated in a limited number of metro cities, leaving large parts of the country dependent on constrained cold-chain logistics and time-sensitive distribution networks.

The high capital cost of PET-CT, SPECT-CT, and cyclotron infrastructure represents a further barrier, particularly for standalone diagnostic centers and hospitals outside major metros, where capital budgets and patient volumes may not yet justify the investment. Regulatory complexity is another consideration, as radiopharmaceutical manufacturing, storage, transport, and clinical use require close compliance with Atomic Energy Regulatory Board (AERB) licensing and radiation-safety protocols, adding cost and lead time to new facility rollouts.

A shortage of trained nuclear medicine physicians, radiopharmacists, and imaging technologists further limits the pace at which new capacity can be operationalized, while inconsistent reimbursement for advanced diagnostic and therapeutic radiopharmaceutical procedures under government and private insurance schemes continues to affect patient access and provider adoption economics.

India Nuclear Medicine and Radiopharmaceuticals Market: Key Insights

The report examines the current state of the India nuclear medicine and radiopharmaceuticals market and identifies the principal growth opportunities emerging across the value chain. Some of the key findings include:

• India currently contributes close to 2.2% of the global nuclear medicine market, positioning it well below its share of global disease burden and hinting at significant long-term upside as domestic infrastructure scales.
• The Department of Atomic Energy has channeled dedicated capital toward new reactors and isotope-production infrastructure, including public-private partnership models, to strengthen domestic radioisotope self-sufficiency.
• Asia-Pacific, inclusive of India, China, and Japan, is emerging as the fastest-growing regional radiopharmaceuticals market globally, supported by rising healthcare expenditure and expanding nuclear medicine infrastructure.
• Therapeutic radiopharmaceuticals and radioligand theranostics, particularly Lutetium-177-based agents for oncology indications, represent the fastest-growing product category as Indian oncology centers begin adopting targeted radionuclide therapy.
• Domestic and global manufacturers, including the DAE's Board of Radiation and Isotope Technology (BRIT) and private players such as Jubilant Radiopharma, remain central to India's radiopharmaceutical supply chain, alongside a growing base of independent radiopharmacies and cyclotron operators.
• Hospitals continue to be the leading end-user setting for nuclear medicine procedures in India, reflecting the specialized radiation-handling infrastructure, cold-chain logistics, and multidisciplinary care required for both diagnostic and therapeutic radiopharmaceutical use.
• Given the pace of cancer-care infrastructure expansion, indigenous isotope production, and rising theranostics adoption, the India nuclear medicine and radiopharmaceuticals market is well positioned for sustained double-digit growth through 2035.

India Nuclear Medicine and Radiopharmaceuticals Market Segmentation

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Product Type

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

By Type of Radioisotope

• Technetium-99m (Tc-99m)
• Fluorine-18 (18F-FDG)
• Iodine-131
• Gallium-68
• Lutetium-177
• Yttrium-90
• Thallium-201
• Others

By Imaging Modality

• SPECT / SPECT-CT
• PET / PET-CT
• PET-MRI
• Targeted Radionuclide Therapy

By Application

• Oncology
• Cardiology
• Neurology
• Thyroid and Endocrine Disorders
• Others

By End User

• Hospitals
• Diagnostic Imaging Centers
• Academic and Research Institutes
• Radiopharmacies

India Nuclear Medicine and Radiopharmaceuticals Market: Key Segment Insights

Diagnostic Radiopharmaceuticals Continue to Lead the Market

Diagnostic agents, led by Technetium-99m based tracers and 18F-FDG for PET oncology imaging, currently represent the largest share of India's nuclear medicine market and are expected to retain this leadership through the forecast period. This is underpinned by the well-established clinical role of SPECT and PET imaging in cancer staging, cardiac perfusion assessment, and thyroid evaluation, together with the comparatively lower infrastructure and training barriers associated with diagnostic, as opposed to therapeutic, radiopharmaceuticals.

Oncology Leads Application Segment

Oncology remains the dominant application area for nuclear medicine procedures in India. This dominance is driven by rising cancer incidence, expanding access to PET-CT for cancer staging and treatment-response monitoring, and the emergence of Lutetium-177-based radioligand therapy for prostate cancer and neuroendocrine tumors. Cardiology and neurology follow as significant, fast-growing application areas, supported by increasing use of myocardial perfusion imaging and amyloid PET imaging respectively.

Hospitals Account for the Largest End-User Share

Hospitals continue to represent the leading end-user segment for India's nuclear medicine and radiopharmaceuticals market. This high share is owing to the specialized radiation-safety infrastructure, AERB-compliant handling protocols, and multidisciplinary oncology and cardiology teams required to deliver both diagnostic imaging and therapeutic radiopharmaceutical procedures. Standalone diagnostic imaging centers and dedicated radiopharmacies are, however, expanding at a faster relative pace as isotope-distribution networks mature.

Example Players in the India Nuclear Medicine and Radiopharmaceuticals Market

• Bracco Imaging
• Board of Radiation and Isotope Technology (BRIT), Department of Atomic Energy
• Curium
• Cardinal Health
• GE HealthCare
• Jubilant Radiopharma (Jubilant Pharma)
• Mallinckrodt Pharmaceuticals
• Novartis (Advanced Accelerator Applications)
• Photon Radiopharma and other domestic radiopharmacy operators
• Siemens Healthineers

INDIA NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the India nuclear medicine and radiopharmaceuticals market, focusing on key segments including type of product, type of radioisotope, imaging modality, application, and end user.
• Competitive Landscape: A detailed assessment of radiopharmaceutical manufacturers, isotope producers, and radiopharmacy operators active in India, evaluated across parameters such as year of establishment, product portfolio, manufacturing capacity, and location of operations.
• Company Profiles: In-depth profiles of prominent players engaged in radiopharmaceutical manufacturing, distribution, and nuclear medicine imaging services in India, featuring information on business segments, portfolio, and key initiatives.
• Regulatory Landscape: An overview of the regulatory framework governing radiopharmaceutical manufacturing, transport, and clinical use in India, including Atomic Energy Regulatory Board (AERB) licensing requirements.
• Recent Developments: A detailed analysis of recent partnerships, collaborations, funding and investment activity, capacity expansions, and industry events relevant to India's nuclear medicine and radiopharmaceuticals sector.
• Porter's Five Forces Analysis: A qualitative assessment of the competitive forces shaping India's nuclear medicine and radiopharmaceuticals market.
• Market Impact Analysis: An evaluation of the drivers, restraints, opportunities, and challenges affecting market growth through 2035.

KEY QUESTIONS ANSWERED IN THIS REPORT

• What is the current and future size of the India nuclear medicine and radiopharmaceuticals market?
• What is the projected CAGR of the India nuclear medicine and radiopharmaceuticals market through 2035?
• Which product type, radioisotope, application, and end-user segment currently leads the India market?
• Which region within India offers the strongest near-term growth opportunity?
• Who are the leading companies operating in India's nuclear medicine and radiopharmaceuticals industry?
• What regulatory factors govern radiopharmaceutical manufacturing and use in India?
• What are the primary challenges faced by radiopharmaceutical manufacturers and nuclear medicine providers in India?
• What factors are likely to influence the evolution of this market through the forecast period?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections for the overall India nuclear medicine and radiopharmaceuticals market and its constituent sub-segments, valuable to established market leaders as well as new entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges, empowering distributors, manufacturers, and healthcare providers to make data-driven decisions and capitalize on emerging growth prospects.
• The report supports businesses in identifying future opportunities across India's nuclear medicine value chain and assessing whether those opportunities are worth pursuing, based on segment-level and regional demand patterns.
• The report assists in understanding evolving customer and provider needs, preferences, and procurement behavior, enabling stakeholders to tailor radiopharmaceutical products and distribution strategies more effectively.
• The report equips new entrants with the market intelligence required to build successful go to market and distribution strategies for the India nuclear medicine and radiopharmaceuticals sector.

Additional Benefits

• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated Report if the Report is 6-12 Months Old or Older